Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Infinity Pharmaceuticals
(NQ:
INFI
)
0.0447
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Infinity Pharmaceuticals
< Previous
1
2
3
4
Next >
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 06, 2023
Via
ACCESSWIRE
INFI SHAREHOLDER ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
September 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
INFI NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
September 01, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital, Infinity, and HUB and Encourages Investors to Contact the Firm
September 01, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 01, 2023
Via
ACCESSWIRE
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
August 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
NASDAQ:INFI Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Infinity Pharmaceuticals, Inc.
August 28, 2023
San Diego, CA -- (SBWIRE) -- 08/28/2023 -- An investor, who purchased shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), filed a lawsuit over alleged violations of Federal Securities Laws by...
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, HUB, and Shift4 and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Infinity Pharmaceuticals, Inc. (INFI) Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Infinity Pharmaceuticals, Inc. Securities Class Action
August 24, 2023
From
Robbins LLP
Via
Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI
August 23, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI
August 22, 2023
WHY: NEW YORK, NY - (NewMediaWire) - August 22, 2023 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital and Infinity and Encourages Investors to Contact the Firm
August 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
August 21, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
August 18, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors
August 18, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Applied Infinity Pharmaceuticals, Inc. (INFI)
August 17, 2023
From
Robbins LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors
August 17, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI
August 17, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
July 25, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
July 24, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
July 14, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)
July 10, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
July 05, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
June 15, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI
June 14, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
April 13, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
March 28, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI
February 27, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
INFI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Infinity Pharmaceuticals, Inc. Is Fair to Shareholders
February 23, 2023
From
Halper Sadeh LLC
Via
Business Wire
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
February 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.